[1-(2,3-二羟基丙氧基羟基磷酰)氧基-3-十四酰氧基丙-2-基]十四酸酯; DMPG | 61361-72-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: [1-(2,3-二羟基丙氧基羟基磷酰)氧基-3-十四酰氧基丙-2-基]十四酸酯; DMPG
• 中文别名: [1-(2,3-二羟基丙氧基羟基磷酰)氧基-3-十四酰氧基丙-2-基]十四酸酯；(S)-1-氨基茚
• 英文名称: dimyristoyl phosphatidylglycerol
• 英文别名: 1,2-dimyristoyl-sn-glycero-3-phospho-rac-glyceol；dimyristoyl phosphatidyl glycerol；dimyristoylphosphatidyl glycerol；dimyristoylphosphatidylglycerol；DMPG；[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate
• CAS: 61361-72-6
• 化学式: C₃₄H₆₇O₁₀P
• 分子量: 666.874
• InChiKey: BPHQZTVXXXJVHI-UHFFFAOYSA-N

物化性质

• 沸点：
  725.9±70.0 °C(Predicted)
• 密度：
  1.063

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  45
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  149
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  [1-(2,3-二羟基丙氧基羟基磷酰)氧基-3-十四酰氧基丙-2-基]十四酸酯; DMPG 、 3,5-二羟基甲苯 、 Escherichia coli lipid A 、 、 氯化钠 以 叔丁醇 为溶剂， 生成 二甲基二碳酸盐
  参考文献：
  名称：

  Method for preparation of vesicles loaded with biological structures,

  摘要：

  一种用于制备负载生物细胞结构、生物聚合物和/或寡聚物的脂质体的组合物，通过在极性原子溶剂中溶解两性材料（如磷脂类），该溶剂可与水混溶，将生物细胞结构、生物聚合物和/或寡聚物在水介质中溶解，将含有两性材料的极性原子溶剂与含有生物细胞结构、生物聚合物和/或寡聚物的水介质混合，并通过冻干法制备干燥产物。将干燥产物在水介质中水合形成负载脂质体。极性原子溶剂可以是叔丁醇，水介质可以含有盐（如氯化钠）、等渗保护剂（如乳糖、蔗糖或海藻糖）或盐和保护剂的混合物。通过将负载脂质体与药学上可接受的载体混合形成治疗疾病的药物。

  公开号：

  US06066331A1
• 作为产物：
  描述：

  cyclosporin A 生成 [1-(2,3-二羟基丙氧基羟基磷酰)氧基-3-十四酰氧基丙-2-基]十四酸酯; DMPG
  参考文献：
  名称：

  Liposomal cyclosporin pharmaceutical formulations

  摘要：

  描述了一种改进的脂质体环孢霉素治疗配方，包括磷脂酰胆碱、磷脂酰甘油和环孢霉素，摩尔比为25:3:1至17:3:1。该配方包括具有降低毒性的单层囊泡。该配方用作免疫抑制剂，是增强抗肿瘤药物对耐药癌细胞效力的增强剂。还提供了一种抑制癌细胞生长的方法。

  公开号：

  EP0697214A1

文献信息

• Bersch, B.; Starck, J. P.; Milon, A., Bulletin de la Societe Chimique de France, 1993, vol. 130, p. 575 - 583
  作者：Bersch, B.、Starck, J. P.、Milon, A.、Nakatani, Y.、Ourisson, G.

  DOI：——

  日期：——
• C70-Containing Liposome, Method for Producing the Same, and Use of the Same
  申请人：Ikeda Atsushi

  公开号：US20100278885A1

  公开（公告）日：2010-11-04

  A solution containing a C 70 cyclodextrin complex and a solution containing a lipid that is capable of forming a liposome are mixed together at a temperature in a range of 10° C. to 45° C. This produces a C 70 -incorporated liposome which keeps a physical property that the C 70 fullerene originally has, and is stably solubilized in a polar solvent. Hence, the present invention provides a C 70 -incorporated liposome which keeps a physical property that the C 70 fullerene originally has, and which is stably solubilized in a polar solvent, a production method of the same, and a use of the same.
• Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof
  申请人：Nammi Therapeutics, Inc.

  公开号：US20210163418A1

  公开（公告）日：2021-06-03

  Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
• Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereof
  申请人：Nammi Therapeutics, Inc.

  公开号：US20220401451A1

  公开（公告）日：2022-12-22

  Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising AR Prodrugs and methods of making the nanocarriers are disclosed herein. The AR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit A2aR. The AR Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
• US8263117B2
  申请人：——

  公开号：US8263117B2

  公开（公告）日：2012-09-11